Crinetics Pharmaceuticals, Inc. (CRNX)

Data as of Sep 1, 2026, from SEC Form 4 filings.

No open-market insider trades (90d)Watch CRNX

See up to 3 months of CRNX. The 7-day demo opens the 1M and 3M ranges and puts CRNX on your watchlist.

Latest CRNX insider trades

Coelho Rogerio Vivaldi - Director
Open-market sale$120K
Jul 2, 2026
Stephanie Okey - Director
Open-market sale$224K
Jun 17, 2026

About Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals, Inc. files with the SEC under CIK 0001658247 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.

Sector: Health Care

SEC filings for CRNX on EDGAR

CRNX Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares
Grant or award	1	471
Option exercise	8	39,856
Derivative transaction	102	5,565,403

Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.

CRNX insider transactions (Form 4)

159

48 Form 4 filings on record, the earliest from Oct 7, 2024, newest first. Filing history page 1 of 2.

Date	Insider	Transaction	Security	Shares	Price	Value
Sep 1, 2026	Wendell Wierenga - Director	Derivative	Common Stock	116,146	$85.00^{footnote F1}	$9.87M
Sep 1, 2026	Wendell Wierenga - Director	Derivative	Common Stock	5,925	$85.00^{footnote F2}	$504K
Sep 1, 2026	Wendell Wierenga - Director	Derivative	Stock Option (Right to Buy)	12,500	$61.76^{footnote F3,F4}	$772K
Sep 1, 2026	Wendell Wierenga - Director	Derivative	Stock Option (Right to Buy)	12,500	$61.77^{footnote F3,F4}	$772K
Sep 1, 2026	Wendell Wierenga - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.77^{footnote F3,F4}	$1.13M
Sep 1, 2026	Wendell Wierenga - Director	Derivative	Stock Option (Right to Buy)	17,500	$66.71^{footnote F3,F4}	$1.17M
Sep 1, 2026	Wendell Wierenga - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.68^{footnote F3,F4}	$1.13M
Sep 1, 2026	Wendell Wierenga - Director	Derivative	Stock Option (Right to Buy)	12,500	$40.29^{footnote F3,F4}	$504K
Sep 1, 2026	Wendell Wierenga - Director	Derivative	Stock Option (Right to Buy)	10,350	$52.67^{footnote F3,F4}	$545K
Sep 1, 2026	Wendell Wierenga - Director	Derivative	Stock Option (Right to Buy)	9,730	$49.13^{footnote F3,F4}	$478K
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Sep 1, 2026	Coelho Rogerio Vivaldi - Director	Derivative	Common Stock	13,300	$85.00^{footnote F1}	$1.13M
Sep 1, 2026	Coelho Rogerio Vivaldi - Director	Derivative	Common Stock	5,925	$85.00^{footnote F2}	$504K
Sep 1, 2026	Coelho Rogerio Vivaldi - Director	Derivative	Stock Option (Right to Buy)	35,000	$56.69^{footnote F3,F4}	$1.98M
Sep 1, 2026	Coelho Rogerio Vivaldi - Director	Derivative	Stock Option (Right to Buy)	8,750	$66.71^{footnote F3,F4}	$584K
Sep 1, 2026	Coelho Rogerio Vivaldi - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.68^{footnote F3,F4}	$1.13M
Sep 1, 2026	Coelho Rogerio Vivaldi - Director	Derivative	Stock Option (Right to Buy)	12,500	$40.29^{footnote F3,F4}	$504K
Sep 1, 2026	Coelho Rogerio Vivaldi - Director	Derivative	Stock Option (Right to Buy)	10,350	$52.67^{footnote F3,F4}	$545K
Sep 1, 2026	Coelho Rogerio Vivaldi - Director	Derivative	Stock Option (Right to Buy)	9,730	$49.13^{footnote F3,F4}	$478K
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Sep 1, 2026	Stephanie Okey - Director	Derivative	Common Stock	6,400	$85.00^{footnote F1}	$544K
Sep 1, 2026	Stephanie Okey - Director	Derivative	Common Stock	5,925	$85.00^{footnote F2}	$504K
Sep 1, 2026	Stephanie Okey - Director	Derivative	Stock Option (Right to Buy)	25,000	$60.85^{footnote F3,F4}	$1.52M
Sep 1, 2026	Stephanie Okey - Director	Derivative	Stock Option (Right to Buy)	12,500	$61.77^{footnote F3,F4}	$772K
Sep 1, 2026	Stephanie Okey - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.77^{footnote F3,F4}	$1.13M
Sep 1, 2026	Stephanie Okey - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.68^{footnote F3,F4}	$1.13M
Sep 1, 2026	Stephanie Okey - Director	Derivative	Stock Option (Right to Buy)	12,500	$40.29^{footnote F3,F4}	$504K
Sep 1, 2026	Stephanie Okey - Director	Derivative	Stock Option (Right to Buy)	10,350	$52.67^{footnote F3,F4}	$545K
Sep 1, 2026	Stephanie Okey - Director	Derivative	Stock Option (Right to Buy)	9,730	$49.13^{footnote F3,F4}	$478K
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Sep 1, 2026	Weston Nichols - Director	Derivative	Common Stock	16,300	$85.00^{footnote F1}	$1.39M
Sep 1, 2026	Weston Nichols - Director	Derivative	Common Stock	5,925	$85.00^{footnote F2}	$504K
Sep 1, 2026	Weston Nichols - Director	Derivative	Stock Option (Right to Buy)	12,500	$61.76^{footnote F3,F4}	$772K
Sep 1, 2026	Weston Nichols - Director	Derivative	Stock Option (Right to Buy)	12,500	$61.77^{footnote F3,F4}	$772K
Sep 1, 2026	Weston Nichols - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.77^{footnote F3,F4}	$1.13M
Sep 1, 2026	Weston Nichols - Director	Derivative	Stock Option (Right to Buy)	17,500	$66.71^{footnote F3,F4}	$1.17M
Sep 1, 2026	Weston Nichols - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.68^{footnote F3,F4}	$1.13M
Sep 1, 2026	Weston Nichols - Director	Derivative	Stock Option (Right to Buy)	12,500	$40.29^{footnote F3,F4}	$504K
Sep 1, 2026	Weston Nichols - Director	Derivative	Stock Option (Right to Buy)	10,350	$52.67^{footnote F3,F4}	$545K
Sep 1, 2026	Weston Nichols - Director	Derivative	Stock Option (Right to Buy)	9,730	$49.13^{footnote F3,F4}	$478K
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Sep 1, 2026	Matthew K. Fust - Director	Derivative	Common Stock	22,836	$85.00^{footnote F1}	$1.94M
Sep 1, 2026	Matthew K. Fust - Director	Derivative	Common Stock	5,925	$85.00^{footnote F2}	$504K
Sep 1, 2026	Matthew K. Fust - Director	Derivative	Stock Option (Right to Buy)	2,092	$83.09^{footnote F3,F4}	$174K
Sep 1, 2026	Matthew K. Fust - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.68^{footnote F3,F4}	$1.13M
Sep 1, 2026	Matthew K. Fust - Director	Derivative	Stock Option (Right to Buy)	12,500	$40.29^{footnote F3,F4}	$504K
Sep 1, 2026	Matthew K. Fust - Director	Derivative	Stock Option (Right to Buy)	10,350	$52.67^{footnote F3,F4}	$545K
Sep 1, 2026	Matthew K. Fust - Director	Derivative	Stock Option (Right to Buy)	9,730	$49.13^{footnote F3,F4}	$478K
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Sep 1, 2026	Caren Deardorf - Director	Derivative	Common Stock	16,300	$85.00^{footnote F1}	$1.39M
Sep 1, 2026	Caren Deardorf - Director	Derivative	Common Stock	5,925	$85.00^{footnote F2}	$504K
Sep 1, 2026	Caren Deardorf - Director	Derivative	Stock Option (Right to Buy)	35,000	$65.70^{footnote F3,F4}	$2.30M
Sep 1, 2026	Caren Deardorf - Director	Derivative	Stock Option (Right to Buy)	4,375	$66.71^{footnote F3,F4}	$292K
Sep 1, 2026	Caren Deardorf - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.68^{footnote F3,F4}	$1.13M
Sep 1, 2026	Caren Deardorf - Director	Derivative	Stock Option (Right to Buy)	12,500	$40.29^{footnote F3,F4}	$504K
Sep 1, 2026	Caren Deardorf - Director	Derivative	Stock Option (Right to Buy)	10,350	$52.67^{footnote F3,F4}	$545K
Sep 1, 2026	Caren Deardorf - Director	Derivative	Stock Option (Right to Buy)	9,730	$49.13^{footnote F3,F4}	$478K
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Sep 1, 2026	Camille L. Bedrosian - Director	Derivative	Common Stock	16,300	$85.00^{footnote F1}	$1.39M
Sep 1, 2026	Camille L. Bedrosian - Director	Derivative	Common Stock	5,925	$85.00^{footnote F2}	$504K
Sep 1, 2026	Camille L. Bedrosian - Director	Derivative	Stock Option (Right to Buy)	25,000	$68.92^{footnote F3,F4}	$1.72M
Sep 1, 2026	Camille L. Bedrosian - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.77^{footnote F3,F4}	$1.13M
Sep 1, 2026	Camille L. Bedrosian - Director	Derivative	Stock Option (Right to Buy)	17,500	$66.71^{footnote F3,F4}	$1.17M
Sep 1, 2026	Camille L. Bedrosian - Director	Derivative	Stock Option (Right to Buy)	17,500	$64.68^{footnote F3,F4}	$1.13M
Sep 1, 2026	Camille L. Bedrosian - Director	Derivative	Stock Option (Right to Buy)	12,500	$40.29^{footnote F3,F4}	$504K
Sep 1, 2026	Camille L. Bedrosian - Director	Derivative	Stock Option (Right to Buy)	10,350	$52.67^{footnote F3,F4}	$545K
Sep 1, 2026	Camille L. Bedrosian - Director	Derivative	Stock Option (Right to Buy)	9,730	$49.13^{footnote F3,F4}	$478K
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Sep 1, 2026	Isabel Kalofonos - Officer	Derivative	Common Stock	1,669^{footnote F1}	$85.00^{footnote F2}	$142K
Sep 1, 2026	Isabel Kalofonos - Officer	Derivative	Common Stock	34,000	$85.00^{footnote F3}	$2.89M
Sep 1, 2026	Isabel Kalofonos - Officer	Derivative	Stock Option (Right to Buy)	97,500	$44.41^{footnote F4,F5}	$4.33M
Sep 1, 2026	Isabel Kalofonos - Officer	Derivative	Stock Option (Right to Buy)	55,000	$41.21^{footnote F4,F5}	$2.27M
Footnote F1 (shares): Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F5 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Common Stock	58,286^{footnote F1}	$85.00^{footnote F2}	$4.95M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Common Stock	79,650	$85.00^{footnote F3}	$6.77M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	90,514	$83.09^{footnote F4,F5}	$7.52M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	74,540	$75.72^{footnote F4,F5}	$5.64M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	56,250	$59.81^{footnote F4,F5}	$3.36M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	60,000	$62.39^{footnote F4,F5}	$3.74M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	85,000	$69.71^{footnote F4,F5}	$5.93M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	15,000	$61.81^{footnote F4,F5}	$927K
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	77,000	$64.98^{footnote F4,F5}	$5.00M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	110,000	$65.36^{footnote F4,F5}	$7.19M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	87,000	$41.49^{footnote F4,F5}	$3.61M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	65,000	$48.14^{footnote F4,F5}	$3.13M
Sep 1, 2026	Stephen F. Betz - Officer	Derivative	Stock Option (Right to Buy)	47,000	$41.21^{footnote F4,F5}	$1.94M
Footnote F1 (shares): Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan. Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F5 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Sep 1, 2026	Tobin Schilke - Officer	Derivative	Common Stock	7,956	$85.00^{footnote F1}	$676K
Sep 1, 2026	Tobin Schilke - Officer	Derivative	Common Stock	71,471	$85.00^{footnote F2}	$6.08M
Sep 1, 2026	Tobin Schilke - Officer	Derivative	Stock Option (Right to Buy)	80,000	$51.25^{footnote F3,F4}	$4.10M
Sep 1, 2026	Tobin Schilke - Officer	Derivative	Stock Option (Right to Buy)	50,000	$41.21^{footnote F3,F4}	$2.06M
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	248,043	$85.00^{footnote F1}	$21.08M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	1,000	$85.00^{footnote F1}	$85K
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	136,805	$85.00^{footnote F1}	$11.63M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	106,000	$85.00^{footnote F1}	$9.01M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	110,000	$85.00^{footnote F1}	$9.35M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	100,000	$85.00^{footnote F1}	$8.50M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	111,100	$85.00^{footnote F1}	$9.44M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	111,100	$85.00^{footnote F1}	$9.44M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	111,100	$85.00^{footnote F1}	$9.44M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	111,100	$85.00^{footnote F1}	$9.44M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	80,000	$85.00^{footnote F1}	$6.80M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Common Stock	176,663	$85.00^{footnote F2}	$15.02M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Stock Option (Right to Buy)	172,281	$59.81^{footnote F3,F4}	$10.30M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Stock Option (Right to Buy)	195,578	$62.39^{footnote F3,F4}	$12.20M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Stock Option (Right to Buy)	259,058	$69.71^{footnote F3,F4}	$18.06M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Stock Option (Right to Buy)	244,205	$64.98^{footnote F3,F4}	$15.87M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Stock Option (Right to Buy)	287,700	$65.36^{footnote F3,F4}	$18.80M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Stock Option (Right to Buy)	240,000	$41.49^{footnote F3,F4}	$9.96M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Stock Option (Right to Buy)	313,000	$48.14^{footnote F3,F4}	$15.07M
Sep 1, 2026	Richard Scott Struthers - Officer	Derivative	Stock Option (Right to Buy)	228,000	$41.21^{footnote F3,F4}	$9.40M
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR
Aug 20, 2026	Tobin Schilke - Officer	Grant or award	Common Stock	471	$0.00^{footnote F1}	-
Footnote F1 (price): The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on September 1, 2027.
Aug 7, 2026	Richard Scott Struthers - Officer	Option exercise	Common Stock	3,969	$25.19	$100K
Aug 7, 2026	Richard Scott Struthers - Officer	Option exercise	Common Stock	4,422	$22.61	$100K
Aug 7, 2026	Richard Scott Struthers - Officer	Option exercise	Common Stock	6,542	$15.29	$100K
Aug 7, 2026	Richard Scott Struthers - Officer	Option exercise	Common Stock	4,995	$20.02	$100K
Aug 7, 2026	Richard Scott Struthers - Officer	Option exercise	Stock Option (Right to Buy)	3,969	$0.00	-
Aug 7, 2026	Richard Scott Struthers - Officer	Option exercise	Stock Option (Right to Buy)	4,422	$0.00	-
Aug 7, 2026	Richard Scott Struthers - Officer	Option exercise	Stock Option (Right to Buy)	6,542	$0.00	-
Aug 7, 2026	Richard Scott Struthers - Officer	Option exercise	Stock Option (Right to Buy)	4,995	$0.00	-
Jul 2, 2026	Coelho Rogerio Vivaldi - Director	Open-market sale	Common Stock	3,000	$40.00^{footnote F2}	$120K
Footnote F2 (price): The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $40.00 per share.
Jun 18, 2026	Caren Deardorf - Director	Grant or award	Stock Option (Right to Buy)	9,730	$0.00	-
Jun 18, 2026	Caren Deardorf - Director	Grant or award	Common Stock	5,925	$0.00^{footnote F1}	-
Footnote F1 (price): The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual… Full note on SEC EDGAR
Jun 18, 2026	Matthew K. Fust - Director	Grant or award	Stock Option (Right to Buy)	9,730	$0.00	-
Jun 18, 2026	Matthew K. Fust - Director	Grant or award	Common Stock	5,925	$0.00^{footnote F1}	-
Footnote F1 (price): The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual… Full note on SEC EDGAR
Jun 18, 2026	Weston Nichols - Director	Grant or award	Common Stock	5,925	$0.00^{footnote F1}	-
Jun 18, 2026	Weston Nichols - Director	Grant or award	Stock Option (Right to Buy)	9,730	$0.00	-
Footnote F1 (price): The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual… Full note on SEC EDGAR
Jun 18, 2026	Coelho Rogerio Vivaldi - Director	Grant or award	Stock Option (Right to Buy)	9,730	$0.00	-
Jun 18, 2026	Coelho Rogerio Vivaldi - Director	Grant or award	Common Stock	5,925	$0.00^{footnote F1}	-
Footnote F1 (price): The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual… Full note on SEC EDGAR
Jun 18, 2026	Camille L. Bedrosian - Director	Grant or award	Stock Option (Right to Buy)	9,730	$0.00	-
Jun 18, 2026	Camille L. Bedrosian - Director	Grant or award	Common Stock	5,925	$0.00^{footnote F1}	-
Footnote F1 (price): The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual… Full note on SEC EDGAR
Jun 18, 2026	Wendell Wierenga - Director	Grant or award	Common Stock	5,925	$0.00^{footnote F1}	-
Jun 18, 2026	Wendell Wierenga - Director	Grant or award	Stock Option (Right to Buy)	9,730	$0.00	-
Footnote F1 (price): The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual… Full note on SEC EDGAR
Jun 18, 2026	Stephanie Okey - Director	Grant or award	Stock Option (Right to Buy)	9,730	$0.00	-
Jun 18, 2026	Stephanie Okey - Director	Grant or award	Common Stock	5,925	$0.00^{footnote F1}	-
Footnote F1 (price): The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual… Full note on SEC EDGAR
Jun 17, 2026	Stephanie Okey - Director	Open-market sale	Common Stock	6,292^{footnote F1}	$35.62^{footnote F2}	$224K
Jun 17, 2026	Stephanie Okey - Director	Open-market sale	Common Stock	608^{footnote F1}	$36.22^{footnote F3}	$22K
Footnote F1 (shares): The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025. Footnote F2 (price): The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $35.62 per share. The range of sale prices on the transaction date was $35.19 to $36.06. Detailed information on the exact number… Full note on SEC EDGAR Footnote F3 (price): The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $36.22 per share. The range of sale prices on the transaction date was $36.19 to $36.29. Detailed information on the exact number… Full note on SEC EDGAR
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	111,100	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	222,200	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	222,200	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	222,200	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	222,200	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	80,000	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	80,000	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	111,100	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	111,100	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	111,100	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	111,100	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	111,100	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	111,100	$0.00	-
May 29, 2026	Richard Scott Struthers - Officer	Gift	Common Stock	111,100	$0.00	-
Apr 8, 2026	Jeff E. Knight - Officer	Option exercise	Common Stock	49,474	$23.98	$1.19M
Apr 8, 2026	Jeff E. Knight - Officer	Option exercise	Common Stock	9,624	$20.02	$193K
Apr 8, 2026	Jeff E. Knight - Officer	Option exercise	Common Stock	19,336	$19.64	$380K
Apr 8, 2026	Jeff E. Knight - Officer	Open-market sale	Common Stock	85,163	$40.10^{footnote F2}	$3.42M
Apr 8, 2026	Jeff E. Knight - Officer	Option exercise	Stock Option (Right to Buy)	49,474	$0.00	-
Apr 8, 2026	Jeff E. Knight - Officer	Option exercise	Stock Option (Right to Buy)	9,624	$0.00	-
Apr 8, 2026	Jeff E. Knight - Officer	Option exercise	Stock Option (Right to Buy)	19,336	$0.00	-
Footnote F2 (price): The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34. Detailed information on the exact number… Full note on SEC EDGAR
Mar 16, 2026	Jeff E. Knight - Officer	Open-market sale	Common Stock	5,950	$37.11^{footnote F2}	$221K
Mar 16, 2026	Jeff E. Knight - Officer	Open-market sale	Common Stock	3,961	$37.77^{footnote F3}	$150K
Footnote F2 (price): The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can… Full note on SEC EDGAR Footnote F3 (price): The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can… Full note on SEC EDGAR
Mar 16, 2026	Stephen F. Betz - Officer	Open-market sale	Common Stock	6,371	$37.11^{footnote F2}	$236K
Mar 16, 2026	Stephen F. Betz - Officer	Open-market sale	Common Stock	4,241	$37.77^{footnote F3}	$160K
Footnote F2 (price): The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can… Full note on SEC EDGAR Footnote F3 (price): The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can… Full note on SEC EDGAR
Mar 16, 2026	Richard Scott Struthers - Officer	Open-market sale	Common Stock	13,196	$37.11^{footnote F2}	$490K
Mar 16, 2026	Richard Scott Struthers - Officer	Open-market sale	Common Stock	8,785	$37.77^{footnote F3}	$332K
Footnote F2 (price): The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can… Full note on SEC EDGAR Footnote F3 (price): The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can… Full note on SEC EDGAR
Mar 12, 2026	Coelho Rogerio Vivaldi - Director	Open-market sale	Common Stock	523	$36.77^{footnote F3}	$19K
Mar 12, 2026	Coelho Rogerio Vivaldi - Director	Open-market sale	Common Stock	4,477	$36.08^{footnote F2}	$162K
Footnote F2 (price): The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.08 per share. The range of sales prices on the transaction date was $35.65 to $36.53 per share. Detailed information on the… Full note on SEC EDGAR Footnote F3 (price): The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $36.77 per share. The range of sales prices on the transaction date was $36.69 to $36.89 per share. Detailed information on the… Full note on SEC EDGAR
Mar 3, 2026	Stephanie Okey - Director	Open-market sale	Common Stock	3,000	$39.67^{footnote F2}	$119K
Footnote F2 (price): The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $39.67 per share.
Mar 3, 2026	Tobin Schilke - Officer	Open-market sale	Common Stock	6,713	$39.67^{footnote F2}	$266K
Footnote F2 (price): The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can… Full note on SEC EDGAR

Recent CRNX Form 8-K filings

Read CRNX company news

Sep 1, 2026Item 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01

Read the filing on SEC EDGAR

Aug 28, 2026Item 5.07, 9.01

Read the filing on SEC EDGAR

Aug 19, 2026Item 8.01

Read the filing on SEC EDGAR

Aug 14, 2026Item 8.01

Recent CRNX Form 144 notices of proposed sale

An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.

Filed	Filer	Relationship	Shares	Market value	Notice
Jul 2, 2026	-	-	-	-	View on EDGAR
Jul 2, 2026	-	-	-	-

Congress trades in CRNX

All congress trades

Stock trades in CRNX disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.

Member	Type	Traded	Disclosed	Value range	Owner	Days to disclose	Filing
Gilbert Ray Cisneros, Jr.Democrat, CA-31	Sale

CRNX insider trading FAQ

What is the latest insider trade for CRNX?

Crinetics Pharmaceuticals, Inc. (CRNX) had 13 insider filings in the last 90 days, with the most recent on 2026-09-01. The full record for CRNX runs to 48 Form 4 filings, the earliest from 2024-10-07. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying CRNX stock?

No insider purchases of CRNX were filed in the last 90 days.

How many insiders are selling CRNX stock?

No insider sales of CRNX were filed in the last 90 days. 26 sales are on record for this company.

Where can I see CRNX SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects CRNX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Sep 1, 2026 - Wendell Wierenga view on EDGAR
Sep 1, 2026 - Coelho Rogerio Vivaldi view on EDGAR
Sep 1, 2026 - Stephanie Okey view on EDGAR
Sep 1, 2026 - Weston Nichols view on EDGAR
Sep 1, 2026 - Matthew K. Fust view on EDGAR
Sep 1, 2026 - Caren Deardorf view on EDGAR
Sep 1, 2026 - Camille L. Bedrosian view on EDGAR
Sep 1, 2026 - Isabel Kalofonos view on EDGAR
Sep 1, 2026 - Stephen F. Betz view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Form 144 vs Form 4: A Form 144 announces a planned sale; the Form 4 reports it after it happens.
Insider activity in Health Care: Where CRNX's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow CRNX with a 7-day demo

CRNX on your watchlist
Every CRNX Form 4 filing on record
Up to 3 months of CRNX price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Grant or award

471

Option exercise

39,856

Derivative transaction

102

5,565,403

Date

Insider

Transaction

Security

Price

Value

Sep 1, 2026

Wendell Wierenga - Director

Derivative

Common Stock

116,146

$85.00^{footnote F1}

$9.87M

Sep 1, 2026

Wendell Wierenga - Director

Derivative

Common Stock

5,925

$85.00^{footnote F2}

$504K

Sep 1, 2026

Wendell Wierenga - Director

Derivative

Stock Option (Right to Buy)

12,500

$61.76^{footnote F3,F4}

$772K

Sep 1, 2026

Wendell Wierenga - Director

Derivative

Stock Option (Right to Buy)

12,500

$61.77^{footnote F3,F4}

$772K

Sep 1, 2026

Wendell Wierenga - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.77^{footnote F3,F4}

$1.13M

Sep 1, 2026

Wendell Wierenga - Director

Derivative

Stock Option (Right to Buy)

17,500

$66.71^{footnote F3,F4}

$1.17M

Sep 1, 2026

Wendell Wierenga - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.68^{footnote F3,F4}

$1.13M

Sep 1, 2026

Wendell Wierenga - Director

Derivative

Stock Option (Right to Buy)

12,500

$40.29^{footnote F3,F4}

$504K

Sep 1, 2026

Wendell Wierenga - Director

Derivative

Stock Option (Right to Buy)

10,350

$52.67^{footnote F3,F4}

$545K

Sep 1, 2026

Wendell Wierenga - Director

Derivative

Stock Option (Right to Buy)

9,730

$49.13^{footnote F3,F4}

$478K

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR
Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR
Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR
Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR

Sep 1, 2026

Coelho Rogerio Vivaldi - Director

Derivative

Common Stock

13,300

$85.00^{footnote F1}

$1.13M

Sep 1, 2026

Coelho Rogerio Vivaldi - Director

Derivative

Common Stock

5,925

$85.00^{footnote F2}

$504K

Sep 1, 2026

Coelho Rogerio Vivaldi - Director

Derivative

Stock Option (Right to Buy)

35,000

$56.69^{footnote F3,F4}

$1.98M

Sep 1, 2026

Coelho Rogerio Vivaldi - Director

Derivative

Stock Option (Right to Buy)

8,750

$66.71^{footnote F3,F4}

$584K

Sep 1, 2026

Coelho Rogerio Vivaldi - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.68^{footnote F3,F4}

$1.13M

Sep 1, 2026

Coelho Rogerio Vivaldi - Director

Derivative

Stock Option (Right to Buy)

12,500

$40.29^{footnote F3,F4}

$504K

Sep 1, 2026

Coelho Rogerio Vivaldi - Director

Derivative

Stock Option (Right to Buy)

10,350

$52.67^{footnote F3,F4}

$545K

Sep 1, 2026

Coelho Rogerio Vivaldi - Director

Derivative

Stock Option (Right to Buy)

9,730

$49.13^{footnote F3,F4}

$478K

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR
Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR
Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR
Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR

Sep 1, 2026

Stephanie Okey - Director

Derivative

Common Stock

6,400

$85.00^{footnote F1}

$544K

Sep 1, 2026

Stephanie Okey - Director

Derivative

Common Stock

5,925

$85.00^{footnote F2}

$504K

Sep 1, 2026

Stephanie Okey - Director

Derivative

Stock Option (Right to Buy)

25,000

$60.85^{footnote F3,F4}

$1.52M

Sep 1, 2026

Stephanie Okey - Director

Derivative

Stock Option (Right to Buy)

12,500

$61.77^{footnote F3,F4}

$772K

Sep 1, 2026

Stephanie Okey - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.77^{footnote F3,F4}

$1.13M

Sep 1, 2026

Stephanie Okey - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.68^{footnote F3,F4}

$1.13M

Sep 1, 2026

Stephanie Okey - Director

Derivative

Stock Option (Right to Buy)

12,500

$40.29^{footnote F3,F4}

$504K

Sep 1, 2026

Stephanie Okey - Director

Derivative

Stock Option (Right to Buy)

10,350

$52.67^{footnote F3,F4}

$545K

Sep 1, 2026

Stephanie Okey - Director

Derivative

Stock Option (Right to Buy)

9,730

$49.13^{footnote F3,F4}

$478K

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR
Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR
Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR
Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR

Sep 1, 2026

Weston Nichols - Director

Derivative

Common Stock

16,300

$85.00^{footnote F1}

$1.39M

Sep 1, 2026

Weston Nichols - Director

Derivative

Common Stock

5,925

$85.00^{footnote F2}

$504K

Sep 1, 2026

Weston Nichols - Director

Derivative

Stock Option (Right to Buy)

12,500

$61.76^{footnote F3,F4}

$772K

Sep 1, 2026

Weston Nichols - Director

Derivative

Stock Option (Right to Buy)

12,500

$61.77^{footnote F3,F4}

$772K

Sep 1, 2026

Weston Nichols - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.77^{footnote F3,F4}

$1.13M

Sep 1, 2026

Weston Nichols - Director

Derivative

Stock Option (Right to Buy)

17,500

$66.71^{footnote F3,F4}

$1.17M

Sep 1, 2026

Weston Nichols - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.68^{footnote F3,F4}

$1.13M

Sep 1, 2026

Weston Nichols - Director

Derivative

Stock Option (Right to Buy)

12,500

$40.29^{footnote F3,F4}

$504K

Sep 1, 2026

Weston Nichols - Director

Derivative

Stock Option (Right to Buy)

10,350

$52.67^{footnote F3,F4}

$545K

Sep 1, 2026

Weston Nichols - Director

Derivative

Stock Option (Right to Buy)

9,730

$49.13^{footnote F3,F4}

$478K

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR
Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR
Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR
Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR

Sep 1, 2026

Matthew K. Fust - Director

Derivative

Common Stock

22,836

$85.00^{footnote F1}

$1.94M

Sep 1, 2026

Matthew K. Fust - Director

Derivative

Common Stock

5,925

$85.00^{footnote F2}

$504K

Sep 1, 2026

Matthew K. Fust - Director

Derivative

Stock Option (Right to Buy)

2,092

$83.09^{footnote F3,F4}

$174K

Sep 1, 2026

Matthew K. Fust - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.68^{footnote F3,F4}

$1.13M

Sep 1, 2026

Matthew K. Fust - Director

Derivative

Stock Option (Right to Buy)

12,500

$40.29^{footnote F3,F4}

$504K

Sep 1, 2026

Matthew K. Fust - Director

Derivative

Stock Option (Right to Buy)

10,350

$52.67^{footnote F3,F4}

$545K

Sep 1, 2026

Matthew K. Fust - Director

Derivative

Stock Option (Right to Buy)

9,730

$49.13^{footnote F3,F4}

$478K

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR
Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR
Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR
Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR

Sep 1, 2026

Caren Deardorf - Director

Derivative

Common Stock

16,300

$85.00^{footnote F1}

$1.39M

Sep 1, 2026

Caren Deardorf - Director

Derivative

Common Stock

5,925

$85.00^{footnote F2}

$504K

Sep 1, 2026

Caren Deardorf - Director

Derivative

Stock Option (Right to Buy)

35,000

$65.70^{footnote F3,F4}

$2.30M

Sep 1, 2026

Caren Deardorf - Director

Derivative

Stock Option (Right to Buy)

4,375

$66.71^{footnote F3,F4}

$292K

Sep 1, 2026

Caren Deardorf - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.68^{footnote F3,F4}

$1.13M

Sep 1, 2026

Caren Deardorf - Director

Derivative

Stock Option (Right to Buy)

12,500

$40.29^{footnote F3,F4}

$504K

Sep 1, 2026

Caren Deardorf - Director

Derivative

Stock Option (Right to Buy)

10,350

$52.67^{footnote F3,F4}

$545K

Sep 1, 2026

Caren Deardorf - Director

Derivative

Stock Option (Right to Buy)

9,730

$49.13^{footnote F3,F4}

$478K

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR
Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR
Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR
Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR

Sep 1, 2026

Camille L. Bedrosian - Director

Derivative

Common Stock

16,300

$85.00^{footnote F1}

$1.39M

Sep 1, 2026

Camille L. Bedrosian - Director

Derivative

Common Stock

5,925

$85.00^{footnote F2}

$504K

Sep 1, 2026

Camille L. Bedrosian - Director

Derivative

Stock Option (Right to Buy)

25,000

$68.92^{footnote F3,F4}

$1.72M

Sep 1, 2026

Camille L. Bedrosian - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.77^{footnote F3,F4}

$1.13M

Sep 1, 2026

Camille L. Bedrosian - Director

Derivative

Stock Option (Right to Buy)

17,500

$66.71^{footnote F3,F4}

$1.17M

Sep 1, 2026

Camille L. Bedrosian - Director

Derivative

Stock Option (Right to Buy)

17,500

$64.68^{footnote F3,F4}

$1.13M

Sep 1, 2026

Camille L. Bedrosian - Director

Derivative

Stock Option (Right to Buy)

12,500

$40.29^{footnote F3,F4}

$504K

Sep 1, 2026

Camille L. Bedrosian - Director

Derivative

Stock Option (Right to Buy)

10,350

$52.67^{footnote F3,F4}

$545K

Sep 1, 2026

Camille L. Bedrosian - Director

Derivative

Stock Option (Right to Buy)

9,730

$49.13^{footnote F3,F4}

$478K

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR
Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR
Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR
Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR

Sep 1, 2026

Isabel Kalofonos - Officer

Derivative

Common Stock

1,669^{footnote F1}

$85.00^{footnote F2}

$142K

Sep 1, 2026

Isabel Kalofonos - Officer

Derivative

Common Stock

34,000

$85.00^{footnote F3}

$2.89M

Sep 1, 2026

Isabel Kalofonos - Officer

Derivative

Stock Option (Right to Buy)

97,500

$44.41^{footnote F4,F5}

$4.33M

Sep 1, 2026

Isabel Kalofonos - Officer

Derivative

Stock Option (Right to Buy)

55,000

$41.21^{footnote F4,F5}

$2.27M

Footnote F1 (shares): Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR
Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR
Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR
Footnote F5 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Common Stock

58,286^{footnote F1}

$85.00^{footnote F2}

$4.95M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Common Stock

79,650

$85.00^{footnote F3}

$6.77M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

90,514

$83.09^{footnote F4,F5}

$7.52M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

74,540

$75.72^{footnote F4,F5}

$5.64M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

56,250

$59.81^{footnote F4,F5}

$3.36M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

60,000

$62.39^{footnote F4,F5}

$3.74M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

85,000

$69.71^{footnote F4,F5}

$5.93M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

15,000

$61.81^{footnote F4,F5}

$927K

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

77,000

$64.98^{footnote F4,F5}

$5.00M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

110,000

$65.36^{footnote F4,F5}

$7.19M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

87,000

$41.49^{footnote F4,F5}

$3.61M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

65,000

$48.14^{footnote F4,F5}

$3.13M

Sep 1, 2026

Stephen F. Betz - Officer

Derivative

Stock Option (Right to Buy)

47,000

$41.21^{footnote F4,F5}

$1.94M

Footnote F1 (shares): Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.
Footnote F2 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR
Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR
Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR
Footnote F5 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR

Sep 1, 2026

Tobin Schilke - Officer

Derivative

Common Stock

7,956

$85.00^{footnote F1}

$676K

Sep 1, 2026

Tobin Schilke - Officer

Derivative

Common Stock

71,471

$85.00^{footnote F2}

$6.08M

Sep 1, 2026

Tobin Schilke - Officer

Derivative

Stock Option (Right to Buy)

80,000

$51.25^{footnote F3,F4}

$4.10M

Sep 1, 2026

Tobin Schilke - Officer

Derivative

Stock Option (Right to Buy)

50,000

$41.21^{footnote F3,F4}

$2.06M

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger… Full note on SEC EDGAR
Footnote F2 (price): The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective… Full note on SEC EDGAR
Footnote F3 (price): The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested… Full note on SEC EDGAR
Footnote F4 (price): The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the… Full note on SEC EDGAR

Sep 1, 2026